Injective Price Spikes on ETF Plans and Phantom Integration
Injective's price surged by over 17% as the broader crypto market moved higher. This rally was fueled by fresh institutional and ecosystem developments that added momentum to the price increase.
The proposed Injective ETF from 21Shares has filed an S-1 update outlining a potential staking allocation of 40%-60% of the fund's INJ holdings. This development strengthens the narrative surrounding institutional access and wider token utility.
Additionally, Injective has launched on Phantom, enabling users to access and manage INJ through one of the leading wallets in the Solana ecosystem. This integration gives Phantom users a more direct route to interact with Injective-related assets, potentially reducing the friction associated with accessing the network's trading and tokenization ecosystem.
The proposed staking structure could allow the fund to generate additional yield from its INJ holdings while maintaining flexibility around liquidity management. However, the filing update does not confirm regulatory approval or establish a final launch date. The development places Injective among crypto assets attracting attention through potential exchange-traded investment products.